NEFL, a potential tumor suppresser [21, 22, 24], is associated with resistance to cisplatin-based chemotherapy, and re-expression of NEFL in HNC significantly increases the sensitivity of the cells to the drug[25]. Here, NEFL is linked to neoplasm.